NCT06742866View on ClinicalTrials.gov

Efficacy and Safety of Intravenous + Oral Vs. Oral Amiodarone in Preventing Recurrence After Catheter Ablation in Patients with Persistent Atrial Fibrillation

NANot yet recruitingINTERVENTIONAL

Enrollment

418

Participants

Timeline

Start Date

December 16, 2024

Primary Completion Date

June 1, 2026

Study Completion Date

July 1, 2026

Conditions

Atrial Fibrillation (AF)

Interventions

DRUG

Amiodarone Injection

Administer 300 mg of intravenous amiodarone as a loading dose once daily (QD) and 200 mg of oral amiodarone twice daily (BID) within 24 hours postoperatively, and continue for 3 consecutive days.

DRUG

Sodium Chloride Injection 0.9%

Sodium chloride injection as a placebo in an amount equivalent to amiodarone injection.

Trial Locations (1)

Unknown

Shanghai Chest Hospital, Shanghai

All Listed Sponsors

lead

Shanghai Chest Hospital

OTHER

NCT06742866 - Efficacy and Safety of Intravenous + Oral Vs. Oral Amiodarone in Preventing Recurrence After Catheter Ablation in Patients with Persistent Atrial Fibrillation | Biotech Hunter | Biotech Hunter